Business

Moderna stock falls more than 10% as it slashes guidance on low EU sales, tough U.S. vaccine market

Moderna now expects 2024 product revenue to come in between $3 billion and $3.5 billion, down from a previous guidance of $4 billion. 

Previous post Moderna stock falls more than 10% as it slashes guidance on low EU sales, tough U.S. vaccine market
Next post Biogen beats expectations, hikes outlook as Alzheimer’s drug Leqembi and other new products gain traction

More Stories